Hanmi and Janssen sign agreement to develop HM12525A
11 November 2015 | By Victoria White
HM12525A is a novel biologic GLP-1/Glucagon dual receptor agonist to treat diabetes and obesity...
List view / Grid view
11 November 2015 | By Victoria White
HM12525A is a novel biologic GLP-1/Glucagon dual receptor agonist to treat diabetes and obesity...
5 November 2015 | By Victoria White
Sanofi and Hanmi have entered a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments...
28 July 2015 | By Victoria White
Boehringer Ingelheim has entered an exclusive and collaboration agreement for the development and global commercialisation rights of HM61713...